Form	PTO-1449 (modified)		Atty. Docket No.	Serial No.	
			OMRF:004US/SLH	10/028,741	_
List of	Patents and Publications for	Applicant's	Applicant		
OIPE			Shinichiro Kurosawa		
FORMATION DISCLOSURE STATEMENT			Deborah J. Stearns-Kurosawa		
MAR 1 2 2002			Filing Date:	Group:	
3	(Use several sheets if necessar	·y)	December 20, 2001	Unknown 1646	
PADEMARK OF	J.S. Patent Documents	Foreign F	Patent Documents	Other Art	
See Page 1			ee Page 1	See Page 1	

## **U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
cun	A1	5,804,392	9/8/98	Esmon et al.	435	7.1)	6/27/97
an	A2	6,037,450	3/14/00	Esmon et al.	530	350	5/20/98

## **Foreign Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
cin	B1	WO 96/05303	2/22/96	PCT			

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Ref. Citation Init. Des.			Citation
Cu	_	C1	Breckenridge, "Oral Anticoagulant Drugs: Pharmacokinetic Aspects," Semin. Hematol., 15:19-26, 1978.
		C2	Esmon, "Natural Anticoagulants and Their Pathways," in Handbook of Experimental Pharmacology, ed: Born et al., Springer-Verlag, New York; pp. 447-476, 1999.
		C3	Fukudome and Esmon, "Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor," <i>J. Biol. Chem.</i> 269:26486-26491, 1994.
		C4	Fukudome <i>et al.</i> , "The endothelial cell protein C receptor. Cell surface expression and direct ligand binding by the soluble receptor," <i>J Biol Chem.</i> , 271(29):17491-17498, 1996.
		C5	Goldstein et al., "Is Glycohemoglobin Testing Useful in Diabetes Mellitis? Lessons from the Diabetes Control and Complications Trial," Clin. Chem., 40:1637-1640, 1994.
		C6	Hrish et al., "Oral Anticoagulants: Mechanisms of Action, Clinical Effectiveness and Optimal Therapeutic Range," Chest, 114 Supp. 445S-469S, 1998.
		C7	Kurosawa et al., "Identification of Functional Endothelial Protein C Receptor in Plasma," J. Clin. Invest., 100:411-418, 1997.
cen	cen C8		Kurosawa <i>et al.</i> , "Plasma Levels of Endothelial Protein C Receptor are Elevated in Patients with Sepsis and Systemic Lupus Erythmatosus: Lack of Correlation with Thrombomodulin Suggests Different Pathological Processes," <i>Blood</i> , 91:725-727, 1998.

25114601.1

Examiner: (12/29/03)

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)			Atty. Docket No. OMRF:004US/SLH	Serial No. 10/028,741	
List of Patents and Publications for Applicant's  NFORMATION DISCLOSURE STATEMENT			Applicant Shinichiro Kurosawa Deborah J. Stearns-Kurosawa		
2002	(Use several sheets if necess	ary)	Filing Date: December 20, 2001	Group: Unknown 1646	
U.S. Patent Documents Foreign			Patent Documents	Other Art	
See Page 1		See Page 1	See Page 1		

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

SIPE	xam. Infig	Ref. Des.	Citation
MAR 1 2 20	Pur	C9	O'Reilly, "Vitamin K and the Oral Anticoagulant Drugs," Annu. Rev. Med., 27:245-261, 1976.
den . —	\$	C10	Regan et al., "The endothelial cell protein C receptor," J. Biol. Chem. 271:17499-17503, 1996.
& TRADEN	ARI	C11	Riley et al., "Clinical Utilization of the International Normalized Ratio (INR)," J. Clin. Lab. Anal., 14:101-114, 2000.
		C12	Stearns-Kurosawa et al., "Plasma levels of endothelial protein C receptor respond to anticoagulant treatment," Blood, 99(2):526-530, 2002.
_		C13	Stearns-Kurosawa <i>et al.</i> , "The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex," <i>Proc. Nat'l Acad. Sci. USA</i> , 93:10212-10216, 1996.
		C14	Sutcliffe et al., "Aspects of Anticoagulant Action: A Review of the Pharmacology, Metabolism and Toxicology of Warfarin and Cogeners," Rev. Drug Metabol. Drug Interact, 5:225-272, 1987.
		C15	Takahashi et al., "Circulating Thrombomodulin as a Novel Endothelial Cell Marker: Comparison of Its Behavior with von Willebrand Factor and Tissue-Type Plasminogen Activator," Am. J. Hematol., 41:32-39, 1992.
		C16	Takano et al., "Plasma Thrombomodulin in Health and Diseases," Blood, 76:2024-2029, 1990.
		C17	Wada et al., "Plasma Thrombomodulin as a Marker of Vascular Disorders in Thrombotic Thrombocytopenic Purpura and Disseminated Intravascular Coagulation," Am. J. Hematol., 39:20-24, 1992.
	W	C18	Xu et al., "Metalloproteolytic Release of Endothelial Protein C Receptor," J. Bio. Chem., 275:6038-6044, 2000.

25114601.1

EXAMINER: Clawh. K

DATE CONSIDERED: (2/29/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.